Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma, B-Cell × Decitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 28 Myelodysplastic Syndromes 13 Leukemia 8 Recurrence 6 Melanoma 5 Leukemia, Myelomonocytic, Chronic 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Ovarian Neoplasms 3 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Blast Crisis 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasm Metastasis 2 Myelodysplastic-Myeloproliferative Diseases 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Accelerated Phase 2 Leukemia, Biphenotypic, Acute 2 Thrombocytopenia 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden 1 Prostatic Neoplasms 1 Peripheral Blood Stem Cell Transplantation 1 Neuroectodermal Tumors, Primitive 1 Myeloproliferative Disorders 1 Myeloid Malignancies 1 Mesothelioma, Malignant 1 Medulloblastoma 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 25 Rituximab 22 fludarabine 14 Lenalidomide 10 Vincristine 8 Doxorubicin 8 Prednisone 7 Etoposide 7 fludarabine phosphate 6 polatuzumab vedotin 4 Immunotherapy, Adoptive 4 Cytarabine 4 CT-P10 4 Bendamustine Hydrochloride 4 Antigens, CD19 4 tocilizumab 3 Gemcitabine 3 Dexamethasone 3 Carboplatin 3 venetoclax 2 veltuzumab 2 prednylidene 2 ofatumumab 2 obinutuzumab 2 ixazomib 2 ibrutinib 2 etoposide phosphate 2 deltacortene 2 carmustine, poliferprosan 20 drug combination 2 acalabrutinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01799083 2016-01-28

CIK

Chinese PLA General Hospital

Phase 1/2 Unknown

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡